This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013
No relevant literature was identified regarding the comparative clinical and cost-effectiveness of LMWHs used as a single agent versus NOACs for long-term thrombosis prophylaxis and for long-term treatment of DVT and PE.
Subject indexing assigned by CRD
Administration, Oral; Anticoagulants; Heparin, Low-Molecular-Weights; Pulmonary Embolism; Venous Thrombosis
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: email@example.com
Date abstract record published